Every intervention Outliyr has scored for lung and breathing health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for lung and breathing health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
35 of 83 evaluated interventions score 3.0+ out of 10 for lung and breathing health · 7 comparisons
Respiratory use scores 7.5/10 on real, Cochrane-backed mucolytic evidence. In the PANTHEON trial Zheng 2014 (n=1,006), 600 mg twice daily cut COPD exacerbations from 1.49 to 1.16 per patient-year (RR 0.78, 95%…
Read the NAC (N-Acetylcysteine) report →Respiratory scoring is now meaningfully supported by SURMOUNT OSA in obesity related obstructive sleep apnea. The benefit is not a bronchodilator effect. It is mostly weight loss mediated reduction in airway collapsibility…
Read the Tirzepatide report →The practical respiratory read is 7.0/10 for HRV Biofeedback, with Pizzoli et al. 2021 setting the ceiling. Lehrer 2004 asthma RCT documented reduced inhaled corticosteroid requirements over 20 weeks of practice. The…
Read the HRV Biofeedback report →Respiratory health scores 6.5/10. Kunutsor 2017 followed 1,935 men for 25.6 years and found 4 or more weekly sauna sessions associated with a 41 percent lower risk of incident respiratory disease (hazard…
Read the Traditional Sauna (Finnish Dry-Heat) report →Thymosin Alpha-1 respiratory earns 6.5/10 because Cao 2024 anchors the most relevant signal. Thymosin Alpha-1 fits respiratory when immune modulation is medically relevant and monitored rather than casually guessed. The score stays…
Read the Thymosin Alpha-1 report →Respiratory and allergy scores 6.5/10 on the strength of a single clean RCT. Cingi 2008 ran a double-blind placebo-controlled trial in allergic rhinitis and found spirulina significantly improving nasal discharge, sneezing, congestion,…
Read the Spirulina report →The strongest respiratory argument for Molecular Hydrogen is 6.3/10 because Dhillon 2024 reports 25-article systematic review; mixed preliminary clinical evidence, heterogeneity, and need for stronger trials. Zhou 2024 points in the same…
Read the Molecular Hydrogen report →The evidence-weighted call is 6.3/10 for Senolytics in respiratory, led by Yousefzadeh et al. 2018. Justice 2019 IPF pilot found feasibility and physical-function signals with D+Q, not F+Q, with no control group.…
Read the Senolytics report →For respiratory, Ephedrine lands at 6.0/10 because context matters. Historical asthma indication via beta-2 bronchodilation; largely supplanted since the 1980s by beta-2 selective inhalers (albuterol, salmeterol) with vastly better cardiac safety. Bronkaid…
Read the Ephedrine report →The practical respiratory read on Zone 2 Cardio is 5.5/10 because Lang 2024 anchors the strongest signal. The existing rationale points to this narrower claim: Zone 2 improves ventilatory efficiency, exercise tolerance,…
Read the Zone 2 Cardio report →GHK-Cu is a 5.5/10 option for respiratory, especially where the context resembles Pickart et al. 1980. The respiratory score stays at 5.5 because COPD and fibrosis signals are gene-expression or preclinical rather…
Read the GHK-Cu report →Respiratory scoring is 5.5/10 because weight loss can reduce obesity-linked breathing load, reflux, and sleep-apnea severity, but Semaglutide is not a bronchodilator or lung therapy. Moiz 2024 supports the weight-loss magnitude that…
Read the Semaglutide report →The respiratory case for Ozone Therapy is 5.5/10 because Chang 2024 reports Verified audit Track 1 and Track 2 source; supports narrow intradiscal lumbar disc efficacy, especially versus steroid injection at 6…
Read the Ozone Therapy report →The Norwegian 4x4 protocol yields modest respiratory gains, reflected by a 5.0/10 score and supported by the VO2max improvement reported in the original 4 x 4 trial Helgerud 2007. In the Norwegian…
Read the Norwegian 4×4 report →Glycine respiratory earns 5.0/10 because Soh 2024 anchors the most relevant signal. Glycine fits respiratory because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The…
Read the Glycine report →Respiratory support scores 5.0/10, anchored to the same Hemila 2013 Cochrane evidence that drives the immune rating: modest cold-duration shortening and meaningful prophylaxis only in people under extreme physical stress. Beyond the…
Read the Vitamin C (Ascorbic Acid) report →Current evidence gives Whole-Body Vibration a respiratory use-case score of 5.0/10, reflecting a lack of direct pulmonary outcome data (Wang 2024). Whole-Body Vibration may alter breathing patterns during sessions, but no trials…
Read the Whole-Body Vibration report →Early COVID and IPF signals exist but are mostly open-label or small. Di Pierro 2021 reported lower hospitalization with 1000 mg/day quercetin phytosome in 152 outpatients. Di Pierro 2022 improved day 7…
Read the Quercetin report →Respiratory and nasal support scores 5.0/10 because seawater irrigation is the one area with replicated RCTs. Kosec 2025 randomized 64 athletes to isotonic seawater and saw subjective nasal obstruction improve (NOSE score…
Read the Quinton Marine Plasma (Seawater Minerals) report →Rapalog immune trials suggest fewer respiratory infections in some older-adult settings, but RTB101 phase 3 and pneumonitis labeling limit confidence.
Read the Rapamycin report →No direct respiratory evidence was verified. Possible relevance in frailty or critical illness remains indirect and context-specific.
Read the Essential Amino Acids report →Hard intervals improve ventilatory efficiency through higher cardiac output and oxygen utilization, but direct respiratory endpoints are secondary to the cardiorespiratory fitness gains.
Read the Sprinting (Sprint Interval Training) report →No direct respiratory evidence. Do not infer benefit from general mitochondrial or anti-inflammatory mechanisms.
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Rao 2024 shows respiratory off-label hypothesis space around asthma outcomes, but the fetched audit did not expose enough numeric detail for scoring, and no respiratory indication is established. The score remains below…
Read the Metformin report →A single small asthma RCT improved lung function and lowered IL-8, but the evidence is one study in a specific population.
Read the Fucoidan (Brown Seaweed Polysaccharide) report →NAC alone has a mucolytic and respiratory track record, but GlyNAC as a combination has no respiratory outcome trial, so the credit is for the NAC component only. Scores 3.5/10.
Read the GlyNAC (Glycine + N-Acetylcysteine) report →Inhaled glutathione has been studied in cystic fibrosis but missed its primary endpoint; the respiratory case is real but unproven, scoring 3.5/10.
Read the Glutathione (GSH) report →Obstructive sleep apnea is in the TRIUMPH development program and weight loss should reduce apnea burden, but retatrutide-specific peer-reviewed sleep-apnea outcomes are still pending.
Read the Retatrutide report →HBOT is not a lung-performance intervention. Oxygen toxicity and pneumothorax risk are central contraindication issues per Cooper 2026. Score low despite the oxygen delivery framing, because lung disease can increase risk rather…
Read the Hyperbaric Oxygen Therapy report →Antioxidant support for lung tissue is mechanistic. Direct respiratory RCT evidence is limited.
Read the Astaxanthin report →Asthma and airway inflammation data are mixed. Omega-3 is not a reliable respiratory intervention.
Read the Omega-3 report →Respiratory results are mixed. Nasal immune and pollutant detox signals exist, but Wise 2016 found no COPD NRF2 target gene, inflammation, antioxidant, or lung function benefit in 89 patients despite confirmed absorption.…
Read the Sulforaphane report →Cordyceps is a traditional lung tonic and improved ventilatory threshold in Chen 2010, but dedicated respiratory-disease RCTs are low quality and mostly Chinese-language.
Read the Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) report →Respiratory scoring is cautious because TRT can worsen obstructive sleep apnea in susceptible men. It is not a respiratory-performance intervention, and untreated severe sleep apnea is a guideline contraindication.
Read the TRT (Testosterone Replacement Therapy) report →Respiratory use has the largest trial footprint and the most disappointing net result, which is exactly why it sits at the midpoint. The two largest critical-care trials both missed their primary endpoints:…
Read the VIP (Vasoactive Intestinal Peptide) report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Different jobs, same shelf. Quercetin scores 6.8 and curcumin 6.5, which decides nothing. Curcumin wins joints, inflammatory markers, gut and mood. Quercetin wins allergies, blood pressure, uric acid…
Different liver problems. NAC scores 8.0 and TUDCA 6.7, and NAC wins liver detox 8.0 against 6.5, but its liver evidence is toxin and oxidative damage. TUDCA owns…
NAC scores 8.0 and glutathione 6.2, and that gap is real. NAC is the cheaper upstream precursor with a six-decade clinical record, so start there. Glutathione earns its…
Start tirzepatide. It scores 6.1 against retatrutide's 5.6, and the gap is mostly availability and evidence maturity rather than weaker biology. Retatrutide is not approved anywhere, cannot legally…
Spirulina scores 7.0 and chlorella 6.5, so spirulina is the better default for most people. It leads on blood pressure, blood sugar, inflammation and breathing. Chlorella leads on…
Thymosin alpha-1 scores 7.3 and thymalin 5.9, and the gap is about evidence rather than mechanism. Thymosin alpha-1 is a defined molecule with modern meta-analyses behind it and…
Tirzepatide scores 6.1 and semaglutide 6.0, so the overall scores don't pick a winner. Your reason for taking one does. Tirzepatide wins on weight and body composition. Semaglutide…
NAC (N-Acetylcysteine), at 7.5 out of 10 for lung and breathing health. Respiratory use scores 7.5/10 on real, Cochrane-backed mucolytic evidence.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.0 out of 10 for lung and breathing health.
35 of the 83 interventions evaluated for lung and breathing health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
